Differentiation therapy using low‐dose venetoclax in a variant acute promyelocytic leukaemia carrying <scp><i>ZBTB16‐RARA</i></scp>

He, Li; Xiang, Xinrong; Ding, Hong; Jiang, Yu; Xu, Jiajun; Wu, Yu

doi:10.1111/bjh.18476

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, sporadic case reports documented the successful treatment of ATRA/ATO‐resistant variant APLs with venetoclax monotherapy or in combination with chemotherapy (Table 1). 6–10 This is the first study to report on the efficacy and possible mechanisms of venetoclax plus ATRA regimen as a differentiation induction therapy in patients with variant APL carrying TNRC18::RARA . Venetoclax in combination with ATRA possesses advantages in terms of time to CR compared to venetoclax monotherapy and safety profiles compared to venetoclax‐based chemotherapy, especially suitable for older patients who are ineligible for intensive chemotherapy.…”

Section: Figurementioning

confidence: 98%

Venetoclax overcomes resistance to all‐trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion

Xu,

Li,

Wang

et al. 2023

Molecular Carcinogenesis

Self Cite

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is generally driven by PML::RARA, but approximately 2% of variant APL patients do not contain this fusion gene and pose challenges in diagnosis and treatment. Here, we reported an aggressive APL patient with variant TNRC18::RARA fusion gene, who was resistant to standard differentiation induction therapy consisting of all‐trans retinoic acid (ATRA) and arsenic trioxide but achieved complete remission with venetoclax plus ATRA. Mechanistically, venetoclax possesses synergistic effects in ATRA‐induced TNRC18::RARA‐positive cell differentiation.

show abstract

Section: Figurementioning

confidence: 98%